药物释放型血管支架的全球市场:规模，占有率，COVID-19影响分析(2023年～2029年):MedCore

全球药物释放型血管支架的市场规模在2022年估算为1亿560万美金。该市场在预测期间内预计将以1.8％的年复合成长率扩大，并达到1亿1,960万美元。

本报告提供全球药物释放型血管支架市场相关调查，提供市场概要，以及各市场区隔，各地区趋势，竞争情形等资讯。

目录

药物释放型血管支架市场

• 简介
• 市场分析与预测
• 促进因素与阻碍因素
  • 推动市场要素
  • 阻碍市场要素
• 竞争市场占有率分析

The global market for drug-eluting stents had a valuation of $105.6 million in 2022, and it is projected to grow at a CAGR of 1.8% during the forecast period, reaching $119.6 million. The comprehensive report on the market focuses solely on drug-eluting stents and does not include its extended set.

MARKET DATA INCLUDED:

• Unit Sales, Average Selling Prices, Market Size & Growth Trends

• Procedure Numbers

• COVID-19 Impact Analysis

• Market Drivers & Limiters

• Market Forecasts Until 2029, and Historical Data to 2019

• Recent Mergers & Acquisitions

• Company Profiles and Product Portfolios

• Leading Competitors

GLOBAL DRUG-ELUTING STENT MARKET INSIGHTS

The primary driver of the drug-eluting stent market is the lack of competition. Intersect ENT is the sole competitor in the market, which enables the company to maintain higher selling prices, driving up the market value. The company's monopoly on the market is a significant factor in the growth of the drug-eluting stent market.

GLOBAL DRUG-ELUTING STENT MARKET SHARE INSIGHTS

The Global drug-eluting stent market was led by Intersect ENT.

Intersect ENT dominates the drug-eluting stent market with its Propel® family of products. These stents are designed to be used in combination with ethmoid sinus surgery, with different shapes and sizes available to suit different sinus anatomies. The company's product line also includes Sinuva® Sinus Implant, which is used to treat nasal polyps in patients who have undergone previous ethmoid sinus surgery. Both Propel® and Sinuva® implants release the corticosteroid mometasone furoate.

MARKET SEGMENTATION SUMMARY

ENT Drug-Eluting Stent Market - MedCore

RESEARCH SCOPE SUMMARY

• Regions: North America (Canada, United States), Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru, Venezuela), Western Europe (Austria, Benelux, France, Germany, Italy, Portugal, Scandinavia, Spain, Switzerland, U.K.), Central & Eastern Europe (Baltic States, Bulgaria, Croatia, Czech Republic, Greece, Hungary, Kazakhstan, Poland, Romania, Russia, Turkey, Ukraine), Middle East (Bahrain, Iran, Israel, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates), Asia Pacific (Australia, Cambodia, China, Hong Kong, India, Indonesia, Japan, Malaysia, Myanmar, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam), Africa (Algeria, Egypt, Ghana, Kenya, Libya, Morocco, Nigeria, South Africa, Sudan, Uganda)

• Base Year: 2022
• Forecast Period: 2023-2029
• Historical Data: 2019-2022

• Quantitative Data: Market Size, Market Share, Market Growth Rates, Units Sold, Average Selling Prices

• Qualitative Data: COVID-19 Impact, Market Growth Trends, Market Limiters, Competitive Analysis & SWOT for Top Competitors, Mergers & Acquisitions, Company Profiles, Product Portfolios

• Data Sources: Primary Interviews with Industry Leaders, Government Physician Data, Regulatory Data, Hospital Private Data, Import & Export Data.

Read more about iData's 9-Step Research Methodology.

Table of Contents

Drug-Eluting Stent Market

• 12.1 Introduction
• 12.2 Market Analysis and Forecast
• 12.3 Drivers and Limiters
  • 12.3.1 Market Drivers
  • 12.3.2 Market Limiters
• 12.4 Competitive Market Share Analysis

LIST OF CHARTS

• Chart 12-1: Drug-Eluting Stent Market, U.S., 2019 - 2029

LIST OF FIGURES

• Figure 12-1: Drug-Eluting Stent Market, U.S., 2019 - 2029
• Figure 12-2: Leading Competitors, Drug-Eluting Stent Market, U.S., 2022